GNH USA

Europe — EMA

Meropenem Hikma Farmacêutica (Portugal) (Meropenem Anhydrous)

GNH USA supplies Meropenem Hikma (Meropenem), a carbapenem antibiotic for severe intra‑abdominal, urinary, skin, meningitis and sepsis infections.

Meropenem Anhydrous

Request sourcing

1
Pack/s

What is Meropenem Anhydrous?

Meropenem, the active ingredient in Meropenem Hikma Farmacêutica, is a carbapenem antibiotic presented as a sterile powder for intravenous use. It treats severe bacterial infections such as complicated intra‑abdominal infections, complicated urinary tract infections, skin and soft tissue infections, bacterial meningitis and severe sepsis in hospitalized patients.

GNH USA supplies Meropenem Hikma Farmacêutica as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

What is Meropenem Anhydrous used for?

Meropenem is a broad‑spectrum carbapenem used for serious bacterial infections across several organ systems.

- Complicated intra‑abdominal infections: provides bacterial eradication and clinical cure. - Complicated urinary tract infections: achieves rapid resolution of infection. - Skin and soft tissue infections: eliminates pathogenic bacteria and promotes healing. - Bacterial meningitis: penetrates the cerebrospinal fluid to treat meningitic pathogens. - Severe sepsis: offers potent activity against multidrug‑resistant organisms.

What are the side effects of Meropenem Anhydrous?

Meropenem may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Diarrhea: mild to moderate gastrointestinal upset. - Nausea: occasional feeling of queasiness. - Vomiting: occasional emesis. - Headache: transient cranial discomfort. - Rash: mild skin erythema. - Elevated liver enzymes: transient increase in hepatic transaminases.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment. - Severe allergic reactions: anaphylaxis or Stevens‑Johnson syndrome. - Clostridioides difficile colitis: antibiotic‑associated diarrhea. - Hemolytic anemia: rare destruction of red blood cells. - Nephrotoxicity: impaired kidney function in susceptible individuals. - Thrombocytopenia: low platelet counts.

What precautions apply to Meropenem Anhydrous?

When using Meropenem, clinicians should consider several safety measures.

- Renal function: adjust dose in patients with impaired kidney function. - Seizure risk: monitor neurologic status, especially in those with CNS disorders. - Allergies: avoid in individuals with known carbapenem or beta‑lactam hypersensitivity. - Pregnancy and lactation: use only if benefits outweigh potential risks. - Concomitant nephrotoxic drugs: monitor for additive kidney injury. - Store below 25°C: keep in original packaging, protect from moisture and light.

What does Meropenem Anhydrous interact with?

Meropenem can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Valproic acid: may reduce serum levels, risking seizure breakthrough. - Probenecid: can increase meropenem concentrations, raising toxicity risk.

Moderate Interactions (Monitor Closely): - Aminoglycosides: combined nephrotoxicity; monitor renal function. - Loop diuretics: may enhance ototoxic potential when used together. - Anticoagulants: possible alteration of INR; check coagulation parameters.

Frequently asked questions

What infections is Meropenem Hikma used to treat?+
Meropenem Hikma is indicated for severe bacterial infections such as complicated intra‑abdominal infections, complicated urinary tract infections, skin and soft tissue infections, bacterial meningitis and severe sepsis. It is used in hospital settings where broad‑spectrum, high‑potency antimicrobial therapy is required.
How does meropenem work against bacteria?+
Meropenem inhibits bacterial cell wall synthesis by binding to penicillin‑binding proteins. This blocks the cross‑linking of peptidoglycan strands, leading to weakened cell walls and bacterial cell death. Its high affinity for multiple PBPs gives it activity against a wide range of Gram‑negative, Gram‑positive and anaerobic organisms.
What is the usual dose of Meropenem Hikma?+
The specific dose of Meropenem Hikma is determined by the prescribing clinician based on the type and severity of infection, patient weight, renal function and other clinical factors. Dosage regimens are individualized and should follow local prescribing guidelines.
Is Meropenem safe to use during pregnancy or breastfeeding?+
Safety data for meropenem in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. It should be used only if the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made by the treating physician.
How do I order Meropenem Hikma from GNH USA?+
To place an order, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.
How does Meropenem compare with other carbapenems?+
Meropenem shares the carbapenem class’s broad spectrum and resistance to most beta‑lactamases, similar to imipenem or ertapenem. Compared with imipenem, meropenem has a lower risk of seizures and does not require co‑administration with cilastatin. Its dosing flexibility and stability make it a preferred option for many severe infections.
What are the storage requirements for Meropenem Hikma?+
Meropenem Hikma should be stored below 25 °C in its original packaging, protected from moisture and light. Once reconstituted for intravenous administration, the solution should be used promptly or stored according to the manufacturer’s instructions, typically at refrigerated temperatures for a limited period.
How is Meropenem Hikma administered to patients?+
Meropenem Hikma is supplied as a sterile powder for intravenous infusion. The powder is reconstituted with a suitable diluent and administered by slow IV infusion over 15–30 minutes, according to the prescribing clinician’s instructions and the patient’s clinical condition.
What are the most serious risks associated with Meropenem?+
The most serious risks include the potential for seizures, especially in patients with renal impairment or pre‑existing CNS disorders, and severe allergic reactions such as anaphylaxis. Clinicians should also monitor for Clostridioides difficile‑associated colitis and rare hematologic events like thrombocytopenia.
Who should not receive Meropenem Hikma?+
Meropenem should not be given to patients with a known hypersensitivity to meropenem, other carbapenems, or any beta‑lactam antibiotics. Caution is advised in patients with a history of seizures, severe renal impairment, or those receiving interacting medications that could increase toxicity.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Meropenem Anhydrous
Route
Intravenous Use
Manufacturer
Hikma Farmacêutica (Portugal), S.A.
Origin
EU

Related products

Agenor

Agenor

Meropenem Anhydrous

Medochemie Ltd.
EU
Agenorem

Agenorem

Meropenem Anhydrous

Medochemie Ltd.
EU
Archifar

Archifar

Meropenem Anhydrous

Medochemie Ltd.
EU
Archifar

Archifar

Meropenem Anhydrous

Medochemie Ltd.
EU